Pneumococcal AMC outcomes and impact evaluation

This evaluation assesses the extent to which the Advanced Market Commitment (AMC) pilot has achieved its stated objectives and the overarching goal to “reduce morbidity and mortality from pneumococcal disease by accelerating the development, availability and uptake of pneumococcal conjugate vaccines (PCVs)”. The AMC pilot was started in 2005 and officially launched in 2007 with a collective US$ 1.5 billion commitment from the Bill and Melinda Gates Foundation, Canada, Italy, Norway, Russian Federation and United Kingdom.

Auteurs